We analyzed ADAT2 protein levels in a validation cohort of 13 tumor samples from MT BRCA1 patients (Figure 5a and Table 1) and found that ADAT2 staining was statistically different compared to the control group (WT BRCA1), confirming that ADAT2 high expression was correlated with low expression of BRCA1 in breast tumor samples. Here, ADAT2 is linked to neoplasm.